SHANRONG BIOTECHNOLOGY CORP. Inactive Instrument
Shanrong Biotechnology Corp. Stock Other OTC
Equities
SRBT
US81946R1077
Investment Holding Companies
| Sales 2008 | 692K 952K | Sales 2009 | 1.32M 1.82M | Capitalization | 11.62M 15.97M |
|---|---|---|---|---|---|
| Net income 2008 | -2M -2.75M | Net income 2009 | -5M -6.88M | EV / Sales 2008 | 45.1 x |
| Net Debt 2008 | 2.53M 3.48M | Net Debt 2009 | 2.18M 3M | EV / Sales 2009 | 10.4 x |
| P/E ratio 2008 |
-10.5
x | P/E ratio 2009 |
-2.03
x | Employees | - |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 38.95% |
More Fundamentals
* Assessed data
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Igwealor
CEO | Chief Executive Officer | 53 | 21-08-30 |
Qingping Zheng
BRD | Director/Board Member | - | - |
Guenter Volgger
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Igwealor
CEO | Chief Executive Officer | 53 | 21-08-30 |
Qingping Zheng
BRD | Director/Board Member | - | - |
Shanrong Biotechnology Corp. is a holding company for select biotechnology, health, and wellness operations. The Company owns and operates three patents: Long-lasting preparation of long-term stable intravenous melatonin injectable addressing sepsis, bacterial pathologies, and other inflammatory pathology; new melatonin formulations for the treatment of chemotherapy-resistant tumors addressing cancer (head and neck, prostate, breast, ovarian, melanoma) and injectable melatonin composition for the treatment of viral diseases addressing COVID-19 and other viral diseases.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +180.69% | 6.38B | |
| +1.60% | 1.01B | |
| +2.12% | 981M | |
| +41.91% | 872M | |
| +22.16% | 812M | |
| +1.82% | 664M | |
| +30.30% | 622M | |
| +1.80% | 617M | |
| -.--% | 600M |
